QIAGEN's (QGEN - Free Report) ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) received FDA approval for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs). In this cancer group, blood cells in the bone marrow do not mature to become healthy cells.
The FDA clearance now covers two additional types of MPN: essential thrombocythemia and primary myelofibrosis.
Notably, the ipsogen JAK2 assay is available in Europe and other markets. Per management, the assay makes it simple for hematologists and oncologists to follow recommended diagnostic testing algorithms and international guidelines for patients suspected to have MPNs.
The company is consistently trying to enhance the Molecular Diagnostic segment, which was the highest revenue grosser in the last reported quarter. Notably, the segment contributed 49% to total revenues. In this regard, QIAGEN recently announced the signing of a collaboration agreement with DiaSorin. Post collaboration, QIAGEN’s QuantiFERON-TB diagnostic test will be available in DiaSorin’s LIAISON portfolio of fully automated analyzers.
In cancer diagnosis market too the company has made several development in recent times. Last August, QIAGEN partnered with Clinical Genomics to implement the PAXgene Blood ccfDNA Tube sample collection in Clinical Genomics' Colvera colorectal cancer recurrence assay. In June, the company had received a worldwide license for biomarkers to be used in identifying patients who may have benefitted from immune-oncology therapies in cancer treatment. Also, the company collaborated with global biopharmaceutical company, Bristol-Myers Squibb Company (BMY - Free Report) for the utilization of next-generation sequencing technology to develop gene expression profiles in the same month.
According to a report by Markets and Markets, the Cancer/Tumor Profiling Market is estimated to reach a value of $8.74 billion by 2022, at a CAGR of 10.7%.
For investors keen on investing in molecular diagnostic space, some of the major players to look forward to are Myriad Genetics (MYGN - Free Report) and Genomic Health .
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
QIAGEN's (QGEN - Free Report) ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) received FDA approval for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs). In this cancer group, blood cells in the bone marrow do not mature to become healthy cells.
The FDA clearance now covers two additional types of MPN: essential thrombocythemia and primary myelofibrosis.
Notably, the ipsogen JAK2 assay is available in Europe and other markets. Per management, the assay makes it simple for hematologists and oncologists to follow recommended diagnostic testing algorithms and international guidelines for patients suspected to have MPNs.
The company is consistently trying to enhance the Molecular Diagnostic segment, which was the highest revenue grosser in the last reported quarter. Notably, the segment contributed 49% to total revenues. In this regard, QIAGEN recently announced the signing of a collaboration agreement with DiaSorin. Post collaboration, QIAGEN’s QuantiFERON-TB diagnostic test will be available in DiaSorin’s LIAISON portfolio of fully automated analyzers.
In cancer diagnosis market too the company has made several development in recent times. Last August, QIAGEN partnered with Clinical Genomics to implement the PAXgene Blood ccfDNA Tube sample collection in Clinical Genomics' Colvera colorectal cancer recurrence assay. In June, the company had received a worldwide license for biomarkers to be used in identifying patients who may have benefitted from immune-oncology therapies in cancer treatment. Also, the company collaborated with global biopharmaceutical company, Bristol-Myers Squibb Company (BMY - Free Report) for the utilization of next-generation sequencing technology to develop gene expression profiles in the same month.
According to a report by Markets and Markets, the Cancer/Tumor Profiling Market is estimated to reach a value of $8.74 billion by 2022, at a CAGR of 10.7%.
For investors keen on investing in molecular diagnostic space, some of the major players to look forward to are Myriad Genetics (MYGN - Free Report) and Genomic Health .
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BMY - FREE
Get the latest research report on MYGN - FREE
Get the latest research report on QGEN - FREE